Patents Assigned to B.R.A.H.M.S GmbH
-
Patent number: 11835531Abstract: An in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from the subject and the correlation of the determined level to a potential risk of sustaining an adverse event.Type: GrantFiled: April 8, 2019Date of Patent: December 5, 2023Assignee: B.R.A.H.M.S GmbHInventors: Joachim Struck, S. J. L. Bakker
-
Publication number: 20230176074Abstract: The present invention relates to a method for diagnosing a respiratory tract infection in a subject, comprising determining in a sample from said subject the level of High-Mobility-Group-Protein B1 (HMGB1), and/or determining in a sample from said subject the level of a histone protein, and/or determining in a sample from said subject the level of Insulin-like growth factor binding protein, acid labile subunit (IGFALS), wherein the subject is diagnosed with a bacterial respiratory tract infection when the level of IGFALS is below a predetermined threshold level and/or the level of the histone protein is above a predetermined threshold value, and/or wherein the subject is diagnosed with a respiratory tract infection when the level of HMGB1 is above a predetermined threshold level.Type: ApplicationFiled: April 9, 2021Publication date: June 8, 2023Applicant: B.R.A.H.M.S GmbHInventors: Michael Hausmann, Ingo Curdt, Stefan Gehrig, Christiane Dinter
-
Publication number: 20230160893Abstract: The invention relates to a method for prognosing disease progression in a patient that has or is at risk of developing a severe acute respiratory syndrome (SARS), wherein the method comprises determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in a sample from the patient, wherein said level indicates the severity of SARS progression. The method is in some embodiments configured for use when a patient exhibits symptoms of a severe acute respiratory syndrome (SARS), a patient exhibits symptoms of infection with a SARS-virus, the patient is infected with a SARS-virus, such as a SARS-coronavirus, such as SARS-CoV2.Type: ApplicationFiled: April 6, 2021Publication date: May 25, 2023Applicant: B.R.A.H.M.S GMBHInventors: Stefan Ebmeyer, Manne Krop, Jutta Odarjuk
-
Patent number: 11592450Abstract: The invention relates to a method for the diagnosis and/or risk stratification of invasive fungal infections (IFI)/invasive fungal diseases (IFD) and in particular associated with sepsis or septic shock, wherein a determination of the marker proadrenomedullin (proADM) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM), or contained in a marker combination (panel, cluster), is carried out from a patient to be examined. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.Type: GrantFiled: August 6, 2018Date of Patent: February 28, 2023Assignee: B.R.A.H.M.S GMBHInventors: Thorsten Brenner, Markus Alexander Weigand, Florian Uhle, Darius Cameron Wilson
-
Publication number: 20220260589Abstract: The invention relates to a method for determining whether a subject diagnosed with a cardiovascular disease should be prescribed a remote patient management, the method comprising measuring particular biomarkers in a sample from said patient. The invention therefore relates to a method for therapy guidance, stratification and/or monitoring of a remote patient management for a patient diagnosed with a cardiovascular disease, comprising providing at least one sample of a patient, determining a level of at least one biomarker selected from the group consisting of proADM, proBNP and proANP or fragment(s) and comparing said level of the at least one biomarker to one or more reference values, wherein said level is indicative of prescribing or not prescribing a remote patient management for said patient.Type: ApplicationFiled: March 27, 2020Publication date: August 18, 2022Applicant: B.R.A.H.M.S GmbHInventors: Tobias Stubbe, Jan Wiemer, Jan Kunde, Stefan Gehrig, Friedrich Köhler
-
Patent number: 11402393Abstract: The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints.Type: GrantFiled: September 11, 2017Date of Patent: August 2, 2022Assignee: B.R.A.H.M.S GMBHInventors: Joachim Struck, Christian Nickel, Roland Bingisser, Sven Giersdorf, Oliver Hartmann
-
Publication number: 20220229076Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.Type: ApplicationFiled: March 31, 2022Publication date: July 21, 2022Applicant: B.R.A.H.M.S. GmbHInventors: Aline PEHLA, Stefan Kirsch, Darius Wilson
-
Patent number: 11391742Abstract: The present invention relates to method for detecting a free histone protein in a biological sample of a subject, e.g. using an immunoassay or a mass spectrometric assay. It also pertains to a method for the diagnosis, prognosis, risk assessment, risk stratification and/or therapy control of a disease or medical condition, comprising detecting a free histone protein or peptide fragment thereof in a biological sample of a subject, wherein the presence of said free histone protein or fragment thereof is indicative for said disease or medical condition.Type: GrantFiled: February 9, 2016Date of Patent: July 19, 2022Assignee: B.R.A.H.M.S. GMBHInventors: Maryann Stephanie Vogelsang, Bryan Krastins, Anne Incamps, Andre Schoenichen, Tim Ziera
-
Publication number: 20220221474Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.Type: ApplicationFiled: March 31, 2022Publication date: July 14, 2022Applicant: B.R.A.H.M.S GmbHInventors: Aline PEHLA, Stefan KIRSCH, Darius WILSON
-
Patent number: 11327082Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.Type: GrantFiled: September 13, 2018Date of Patent: May 10, 2022Assignee: B.R.A.H.M.S GmbHInventors: Aline Pehla, Stefan Kirsch, Darius Wilson
-
Patent number: 11241395Abstract: In vitro methods such as in vitro diagnosis, prognosis and risk stratification of a patient having a primary disease, whereby the level of Procalcitonin (PCT) or fragment thereof in a sample of a bodily fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition. Assays for performing such methods and samples containing complex resulting from such methods.Type: GrantFiled: March 29, 2019Date of Patent: February 8, 2022Assignee: B.R.A.H.M.S. GmbHInventors: Joachim Struck, Andreas Bergmann
-
Publication number: 20210405070Abstract: The invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and/or risk stratification of a subsequent trauma-related complication in a polytrauma patient, comprising providing a sample of said patient, wherein the sample is isolated from the patient after the polytrauma, determining a level of pro ADM or fragment(s) thereof in said sample, wherein said level of pro ADM or fragment(s) thereof correlates with the likelihood of a subsequent trauma-related complicationType: ApplicationFiled: June 6, 2019Publication date: December 30, 2021Applicant: B.R.A.H.M.S GMBHInventors: Darius Wilson, Aline Pehla, Stefan Ebmeyer, Frauke Dreyer
-
Publication number: 20210349089Abstract: The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of a fungal infection, in particular invasive fungal infections (IFI) and/or the ruling in or ruling out of an fungal infection and/or the differential diagnosis of a fungal colonization vs. an invasive fungal infection in a subject, wherein in particular the subject has an increased risk of getting or having a fungal infection and/or the subject is in a critical disease state, particularly has an existing infection and/or a state of sepsis, particularly a septic shock. The method of the invention comprises determining the level of at least one marker selected from the group of ICAM1, AHSG, CPN1, FABP1, HRG, PIGR, RAP1A, THBS1, VCL, ET-1. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.Type: ApplicationFiled: May 31, 2019Publication date: November 11, 2021Applicant: B.R.A.H.M.S GmbHInventors: Janin Schulte, Anne Incamps, Markus Alexander Weigand, Thorsten Brenner
-
Publication number: 20210293830Abstract: The invention relates to a method for therapy guidance, stratification and/or control in a patient with symptoms of an infectious disease, comprising a prognosis of disease progression, the method comprising: providing a sample from said patient, and determining a level of proADM or fragment(s) thereof in said sample, wherein a low risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is not at risk of a disease progression to a condition that requires hospitalization, wherein said low risk level is preferably equal or below 1.2 nmol/l±20%, and/or wherein a high risk level of proADM level or fragment(s) thereof in said sample indicates that the patient is at risk of a disease progression to a condition that requires hospitalization, wherein said high risk level is preferably above 1.2 nmol/l±20%. The invention further relates to a test kit for carrying out the method.Type: ApplicationFiled: August 8, 2019Publication date: September 23, 2021Applicants: B.R.A.H.M.S GmbH, Instituto de Investigación Biomédica de SalamancaInventors: Darius Wilson, Jesús Francisco Bermejo Martin, Luis Garcia Ortiz, Carmen Herrero Rodriguez
-
Patent number: 11041867Abstract: The present invention relates to diagnosis, prognosis, risk assessment, and/or risk stratification of an adverse event, particularly mortality, of a subject. The invention relates to a method that comprises determining a level of proadrenomedullin (proADM) in a sample of said subject, and wherein said level of proADM is indicative of said adverse event of said subject, wherein said level of proADM is compared to a reference level of proADM; and wherein said adverse event of said subject is identified based on the comparison. The invention further relates to kits for carrying out the methods of the invention.Type: GrantFiled: February 1, 2018Date of Patent: June 22, 2021Assignee: B.R.A.H.M.S GmbHInventors: Darius Cameron Wilson, Jesus Bermejo, David Andaluz, Dolores Calvo
-
Publication number: 20210109117Abstract: The present invention is in the field of clinical diagnostics. Particularly, the present invention relates to the assessment of severity of a subject being suspected of an infection or having an infection, who may have physiological signs or increased risk factors for infection, in particular from an infectious disease by determination of the levels of Procalcitonin (hereinafter: PCT) (SEQ ID No: 1 and/or proadrenomedullin (hereinafter: proADM)) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular midregional proadrenomedullin (MR-proADM) (SEQ ID No: 2), in a sample of a patient and the invention is related to a workflow hereto. Moreover, the invention refers to the assessment related to an infection like ruling out/in a patient and stratification, risk assessment, in particular to avoid rehospitalisation and hospital and post-discharge mortality.Type: ApplicationFiled: December 20, 2018Publication date: April 15, 2021Applicant: B.R.A.H.M.S GmbHInventors: Aline PEHLA, Darius WILSON
-
Publication number: 20210109118Abstract: The invention relates to a method for antibiotic therapy guidance, stratification and/or control in a patient suspected of having an infection. In particular, the method comprises providing a sample form said patient, determining a level of proADM or fragment(s) thereof in said sample, and wherein the level of proADM or fragment(s) thereof in said sample is indicative of whether an initiation or a change of an antibiotic treatment is required. In a preferred embodiment of the invention, the method comprises additionally determining in a sample from said patient a level of PCT or fragment(s) thereof. Furthermore, the invention also relates to a kit for carrying out the method of the present invention.Type: ApplicationFiled: December 20, 2018Publication date: April 15, 2021Applicant: B.R.A.H.M.S GmbHInventor: Darius WILSON
-
Patent number: 10954298Abstract: Method of obtaining and/or verifying a binder to prepro-Vasopressin (SEQ ID NO. 1) or fragments thereof of at least 6 amino acids in length, including Copeptin (SEQ ID NO. 2), comprising at least one of the steps of: a) generating the binder using a developer comprising an amino acid sequence of at least 6 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); b) determining whether the binder is capable of binding to an amino acid sequence of at least 4 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); c) selecting and optionally isolating the binder from a plurality of binders which is capable of binding to an amino acid sequence contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO.Type: GrantFiled: May 1, 2018Date of Patent: March 23, 2021Assignee: B.R.A.H.M.S. GmbHInventor: Joachim Struck
-
Patent number: 10921330Abstract: CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals.Type: GrantFiled: December 11, 2015Date of Patent: February 16, 2021Assignee: B.R.A.H.M.S GMBHInventors: Andreas Bergmann, Andrea Sparwaβer, Harald Hampel
-
Patent number: 10857129Abstract: The present invention relates to a vasopressin receptor 1B (V1B) antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in patients showing an elevated arginine vasopressin (AVP) level and/or an elevated copeptin level. The present invention further relates to a method for predicting the treatment response to a V1B antagonist in patients with depressive symptoms and/or anxiety symptoms.Type: GrantFiled: August 15, 2019Date of Patent: December 8, 2020Assignee: B.R.A.H.M.S GMBHInventor: Florian Holsboer